Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Esperion Therapeutics, Inc is a biotechnology business based in the US. Esperion Therapeutics shares (ESPR) are listed on the NASDAQ and all prices are listed in US Dollars. Esperion Therapeutics employs 193 staff and has a trailing 12-month revenue of around USD$216 million.
|Latest market close||USD$30.08|
|52-week range||USD$24.82 - USD$76.98|
|50-day moving average||USD$36.2253|
|200-day moving average||USD$40.2313|
|Wall St. target price||USD$82.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.863|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||11.49%|
|1 month (2020-11-06)||19.13%|
|3 months (2020-09-04)||-20.84%|
|6 months (2020-06-05)||-33.67%|
|1 year (2019-12-05)||-36.00%|
|2 years (2018-12-04)||-43.79%|
|3 years (2017-12-05)||-48.71%|
|5 years (2015-12-04)||8.16%|
|Revenue TTM||USD$216 million|
|Gross profit TTM||USD$-27,247,000|
|Return on assets TTM||-13.69%|
|Return on equity TTM||-78.17%|
|Market capitalisation||USD$944.7 million|
TTM: trailing 12 months
There are currently 11.1 million Esperion Therapeutics shares held short by investors – that's known as Esperion Therapeutics's "short interest". This figure is 0.3% down from 11.2 million last month.
There are a few different ways that this level of interest in shorting Esperion Therapeutics shares can be evaluated.
Esperion Therapeutics's "short interest ratio" (SIR) is the quantity of Esperion Therapeutics shares currently shorted divided by the average quantity of Esperion Therapeutics shares traded daily (recently around 500390.47619048). Esperion Therapeutics's SIR currently stands at 22.26. In other words for every 100,000 Esperion Therapeutics shares traded daily on the market, roughly 22260 shares are currently held short.
However Esperion Therapeutics's short interest can also be evaluated against the total number of Esperion Therapeutics shares, or, against the total number of tradable Esperion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Esperion Therapeutics's short interest could be expressed as 0.4% of the outstanding shares (for every 100,000 Esperion Therapeutics shares in existence, roughly 400 shares are currently held short) or 0.4657% of the tradable shares (for every 100,000 tradable Esperion Therapeutics shares, roughly 466 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Esperion Therapeutics.
Find out more about how you can short Esperion Therapeutics stock.
We're not expecting Esperion Therapeutics to pay a dividend over the next 12 months.
Esperion Therapeutics's shares were split on a 1:6 basis on 11 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Esperion Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Esperion Therapeutics shares which in turn could have impacted Esperion Therapeutics's share price.
Over the last 12 months, Esperion Therapeutics's shares have ranged in value from as little as $24.82 up to $76.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Esperion Therapeutics's is 1.6018. This would suggest that Esperion Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.